The Wall Street firm put big drugmakers' R&D programs through five different tests.
Compare NVO Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: Novo Nordisk
The company is mainly known for its diabetes drugs but has some background in rare-disease drugs.
A new FDA-approved product with the potential to triple weight loss in obesity patients should be a huge win for the company.
This stock could be a great addition to any long-term portfolio.
Which diabetes drug maker will win this photo finish for investors?
Considering business quality is the best way to earn growing payouts over time.
One metric shows that decades of dominance treating diabetes has created unrivaled profitability.
DexCom, Tandem Diabetes, and Novo Nordisk have plenty of momentum and growth ahead, making them excellent buys this month.
These are two worthy contenders for your investment portfolio.
The health insurer hopes that making prescriptions affordable will keep the people it covers healthier, which should save it money in the long run.